QHSLab (USAQ)
OTHER OTC:USAQ
Top Page
QHSLab
(OTC:USAQ)
Select Model
Select Model
Rating:63Neutral
Price Target:
$0.53
▲(8.78% Upside)
Action:ReiteratedDate:04/01/26
The score is driven primarily by the strong 2025 financial turnaround and balance-sheet deleveraging, reinforced by positive corporate actions to simplify the capital structure. This is tempered by weak technical momentum (bearish RSI/MACD and price below key moving averages) and some sustainability questions due to historically volatile results and weaker cash conversion versus reported earnings.
Positive Factors
Profitability Turnaround
The 2025 return to net income with a ~67% gross margin signals a meaningful operational inflection. Sustained high gross margins enhance the firm's ability to reinvest in product development and sales, supporting durable profitability if revenue growth and cost discipline continue beyond one-time items.
Negative Factors
Weak Cash Conversion
Operating cash flow materially lagging reported net income (operating CF <50% of net income) raises earnings quality concerns. Persistent weak cash conversion constrains reinvestment and increases reliance on financing; durable growth requires consistent positive cash conversion.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability Turnaround
The 2025 return to net income with a ~67% gross margin signals a meaningful operational inflection. Sustained high gross margins enhance the firm's ability to reinvest in product development and sales, supporting durable profitability if revenue growth and cost discipline continue beyond one-time items.
Read all positive factors
QHSLab (USAQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.77M
Dividend YieldN/A
Average Volume (3M)6.57K
Price to Earnings (P/E)15.0
Beta (1Y)0.99
Revenue Growth43.55%
EPS Growth-461.90%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.03
Shares Outstanding15,032,788
10 Day Avg. Volume9,209
30 Day Avg. Volume6,568
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.21
Price to Sales (P/S)2.54
P/FCF Ratio38.43
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue2.50
Enterprise Value/Gross Profit3.72
Enterprise Value/Ebitda8.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.3
Revenue Forecast (FY)N/A
QHSLab Business Overview & Revenue Model
Company Description
QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It also develops digital therapeutics and point of care solutions to support...
How the Company Makes Money
null...
QHSLab Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
64
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.69M | 2.13M | 1.41M | 1.24M | 1.41M |
| Gross Profit | 1.81M | 1.36M | 793.61K | 619.52K | 670.75K |
| EBITDA | 785.56K | 352.39K | -91.29K | -434.60K | -487.63K |
| Net Income | 457.42K | -259.24K | -468.36K | -996.00K | -770.18K |
Balance Sheet | |||||
| Total Assets | 2.17M | 1.80M | 1.68M | 1.96M | 2.21M |
| Cash, Cash Equivalents and Short-Term Investments | 636.16K | 157.17K | 51.58K | 178.69K | 286.86K |
| Total Debt | 20.00K | 1.72M | 1.78M | 1.68M | 1.30M |
| Total Liabilities | 546.08K | 2.41M | 2.06M | 1.88M | 1.38M |
| Stockholders Equity | 1.62M | -607.76K | -375.62K | 76.25K | 824.07K |
Cash Flow | |||||
| Free Cash Flow | 178.12K | 142.44K | -159.63K | -388.11K | -509.31K |
| Operating Cash Flow | 178.12K | 142.44K | -159.63K | -350.99K | -354.74K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -37.12K | -154.57K |
| Financing Cash Flow | 300.87K | -36.85K | 32.52K | 279.95K | 701.82K |
QHSLab Technical Analysis
Positive
0.49
Price Trends
0.68
Negative
0.57
Positive
0.38
Positive
Market Momentum
-0.02
Positive
50.39
Neutral
41.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USAQ, the sentiment is Positive. The current price of 0.49 is below the 20-day moving average (MA) of 0.65, below the 50-day MA of 0.68, and above the 200-day MA of 0.38, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 50.39 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for USAQ.
QHSLab Risk Analysis
QHSLab disclosed 45 risk factors in its most recent earnings report. QHSLab reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
QHSLab Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $9.77M | 14.96 | ― | ― | 43.55% | -461.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $2.93M | -0.28 | -191.39% | ― | ― | 76.53% | |
44 Neutral | $2.32M | -115.09 | -173.74% | ― | 82.96% | 82.04% | |
41 Neutral | $2.50M | -0.69 | -6046.59% | ― | -8.93% | 97.80% | |
41 Neutral | $562.87K | -0.05 | -2268.26% | ― | -12.39% | 44.61% |
* Healthcare Sector Average
USAQ
QHSLab
0.65
0.43
196.80%
NUWE
Nuwellis
1.08
-35.04
-97.01%
AEMD
Aethlon Medical
2.23
-26.01
-92.10%
VERO
Venus Concept
0.30
-8.63
-96.62%
VTAK
Catheter Precision
0.86
-4.84
-84.88%
BBLG
Bone Biologics
1.28
-2.73
-68.08%
QHSLab Corporate Events
Business Operations and StrategyFinancial Disclosures
QHSLab Posts 2025 Profit, Revenue Growth and Deleveraging
Positive
Mar 31, 2026
On March 31, 2026, QHSLab reported its fiscal 2025 results, highlighting that revenue rose 26% year over year to about $2.69 million and gross margin widened to 67.3%. The company posted net income of $457,417 versus a loss in 2024, while cash cli...
Business Operations and StrategyFinancial Disclosures
QHSLab Reports 2025 Preliminary Results and Debt Reduction
Positive
Jan 26, 2026
On January 26, 2026, QHSLab reported preliminary unaudited financial results for 2025 showing revenue rose just over 25% to $2.68 million and gross profit increased more than 32% to $1.80 million, with gross margins improving from about 64% to rou...
Business Operations and StrategyPrivate Placements and Financing
QHSLab Simplifies Capital Structure With Debt-for-Equity Deal
Positive
Jan 23, 2026
QHSLab, Inc. entered into a Note Repurchase Agreement with MedScience Research Group, Inc. under which it repurchased, cancelled, and extinguished a promissory note originally issued on June 23, 2021, that had an outstanding principal and accrued ...
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesPrivate Placements and Financing
QHSLab Expands Board to Strengthen Governance and Uplisting Plans
Positive
Jan 16, 2026
On January 16, 2026, QHSLab announced that it has begun a formal process to expand its board of directors by adding independent members, aiming to strengthen corporate governance, enhance oversight, and support future capital markets objectives, i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.